Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.16 which represents a decrease of $-0.10 or -7.94% from the prior close of $1.26. The stock opened at $1.24 and touched a low of $1 ...

Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The ...

Editas Medicine extends its cash runway to Q2 2027 while prioritizing in vivo gene editing programs. JPMorgan downgrades Editas to Underweight, citing unclear timelines and limited near-term ...

Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The firm’s revenue was down 98.9% on a year-over-year basis. During the same period in the prior ...

Evercore ISI analyst Liisa Bayko lowered the firm’s price target on Editas Medicine (EDIT) to $5 from $7 and keeps an Outperform rating on the shares. Editas has decided to cut the reni-cel ...

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...